Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management
Patients with Parkinson disease (PD) experience a range of non-motor symptoms, including gastrointestinal symptoms. These symptoms can be present in the prodromal phase of the disease. Recent advances in pathophysiology reveal that α-synuclein aggregates that form Lewy bodies and neurites, the hallm...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Brain Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3425/11/7/831 |
| _version_ | 1827688968526757888 |
|---|---|
| author | Heithem Soliman Benoit Coffin Guillaume Gourcerol |
| author_facet | Heithem Soliman Benoit Coffin Guillaume Gourcerol |
| author_sort | Heithem Soliman |
| collection | DOAJ |
| description | Patients with Parkinson disease (PD) experience a range of non-motor symptoms, including gastrointestinal symptoms. These symptoms can be present in the prodromal phase of the disease. Recent advances in pathophysiology reveal that α-synuclein aggregates that form Lewy bodies and neurites, the hallmark of PD, are present in the enteric nervous system and may precede motor symptoms. Gastroparesis is one of the gastrointestinal involvements of PD and is characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction. Gastroparesis has been reported in nearly 45% of PD. The cardinal symptoms include early satiety, postprandial fullness, nausea, and vomiting. The diagnosis requires an appropriate test to confirm delayed gastric emptying, such as gastric scintigraphy, or breath test. Gastroparesis can lead to malnutrition and impairment of quality of life. Moreover, it might interfere with the absorption of antiparkinsonian drugs. The treatment includes dietary modifications, and pharmacologic agents both to accelerate gastric emptying and relieve symptoms. Alternative treatments have been recently developed in the management of gastroparesis, and their use in patients with PD will be reported in this review. |
| first_indexed | 2024-03-10T10:08:03Z |
| format | Article |
| id | doaj.art-f130e998709d4b5ab3b3eb1b0e42048f |
| institution | Directory Open Access Journal |
| issn | 2076-3425 |
| language | English |
| last_indexed | 2024-03-10T10:08:03Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Brain Sciences |
| spelling | doaj.art-f130e998709d4b5ab3b3eb1b0e42048f2023-11-22T01:24:11ZengMDPI AGBrain Sciences2076-34252021-06-0111783110.3390/brainsci11070831Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical ManagementHeithem Soliman0Benoit Coffin1Guillaume Gourcerol2Centre de Recherche sur l’Inflammation, Université de Paris, Inserm UMRS 1149, 75018 Paris, FranceCentre de Recherche sur l’Inflammation, Université de Paris, Inserm UMRS 1149, 75018 Paris, FranceCentre Hospitalo-Universitaire de Rouen, INSERM UMR 1073, CIC-CRB 1404, 76000 Rouen, FrancePatients with Parkinson disease (PD) experience a range of non-motor symptoms, including gastrointestinal symptoms. These symptoms can be present in the prodromal phase of the disease. Recent advances in pathophysiology reveal that α-synuclein aggregates that form Lewy bodies and neurites, the hallmark of PD, are present in the enteric nervous system and may precede motor symptoms. Gastroparesis is one of the gastrointestinal involvements of PD and is characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction. Gastroparesis has been reported in nearly 45% of PD. The cardinal symptoms include early satiety, postprandial fullness, nausea, and vomiting. The diagnosis requires an appropriate test to confirm delayed gastric emptying, such as gastric scintigraphy, or breath test. Gastroparesis can lead to malnutrition and impairment of quality of life. Moreover, it might interfere with the absorption of antiparkinsonian drugs. The treatment includes dietary modifications, and pharmacologic agents both to accelerate gastric emptying and relieve symptoms. Alternative treatments have been recently developed in the management of gastroparesis, and their use in patients with PD will be reported in this review.https://www.mdpi.com/2076-3425/11/7/831Parkinson diseasegastroparesisalpha-synucleinvagus nerve |
| spellingShingle | Heithem Soliman Benoit Coffin Guillaume Gourcerol Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management Brain Sciences Parkinson disease gastroparesis alpha-synuclein vagus nerve |
| title | Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management |
| title_full | Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management |
| title_fullStr | Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management |
| title_full_unstemmed | Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management |
| title_short | Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management |
| title_sort | gastroparesis in parkinson disease pathophysiology and clinical management |
| topic | Parkinson disease gastroparesis alpha-synuclein vagus nerve |
| url | https://www.mdpi.com/2076-3425/11/7/831 |
| work_keys_str_mv | AT heithemsoliman gastroparesisinparkinsondiseasepathophysiologyandclinicalmanagement AT benoitcoffin gastroparesisinparkinsondiseasepathophysiologyandclinicalmanagement AT guillaumegourcerol gastroparesisinparkinsondiseasepathophysiologyandclinicalmanagement |